Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076907 | 0.78 | ALDH1A1 (0.43) | TDP1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1077415 | 0.77 | ALDH1A1 (0.50) | TDP1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1075175 | 0.77 | ALDH1A1 (0.40) | TDP1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1075173 | 0.77 | ALDH1A1 (0.40) | TDP1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1075176 | 0.77 | ALDH1A1 (0.40) | TDP1SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1075893 | 0.75 | ALDH1A1 (0.40) | TDP1SMN1; SMN2RECQLMEN1KMT2A | |
| SCHEMBL2308765 | 0.73 | EGFR (0.40) | TDP1SMN1; SMN2RECQLMEN1KMT2A | |
| SCHEMBL2315007 | 0.73 | ALDH1A1 (0.39) | TDP1MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1076313 | 0.73 | KDM4E (0.46) | TDP1MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1077453 | 0.72 | ALDH1A1 (0.41) | TDP1MEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | disclosed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | disclosed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | disclosed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | disclosed |
| EP-2276732-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127686-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | ESR1, GPER1, ESRRA | TDP1 3894/4885SMN1; SMN2 3996/4885RECQL 2935/4885 |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, GPER1, ESRRA | TDP1 3923/4885SMN1; SMN2 4106/4885RECQL 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.